Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.

6 analysts have issued 1 year price objectives for Syndax Pharmaceuticals' stock. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they expect the company's stock price to reach $33.57 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX stock has decreased by 9.1% and is now trading at $23.13.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SNDX earnings forecast.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its earnings results on Tuesday, February, 28th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02.

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3X Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avidity Partners Management LP (9.73%), Frazier Life Sciences Management L.P. (6.16%), Avoro Capital Advisors LLC (4.40%), Jennison Associates LLC (3.82%), Eversept Partners LP (2.69%) and Dimensional Fund Advisors LP (2.10%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich and Pierre Legault.
View institutional ownership trends.

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNDX stock can currently be purchased for approximately $23.13.

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.58 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.